 Antineoplastic Agents, Phytogenic
"Antineoplastic Agents, Phytogenic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.
| Descriptor ID |
D000972
|
| MeSH Number(s) |
D27.505.954.248.179
|
| Concept/Terms |
Antineoplastic Agents, Phytogenic- Antineoplastic Agents, Phytogenic
- Agents, Phytogenic Antineoplastic
- Phytogenic Antineoplastic Agents
- Antineoplastics, Phytogenic
- Phytogenic Antineoplastics
- Antineoplastics, Botanical
- Botanical Antineoplastics
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents, Phytogenic".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents, Phytogenic".
This graph shows the total number of publications written about "Antineoplastic Agents, Phytogenic" by people in this website by year, and whether "Antineoplastic Agents, Phytogenic" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 | | 2006 | 2 | 1 | 3 | | 2008 | 2 | 0 | 2 | | 2015 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Antineoplastic Agents, Phytogenic" by people in Profiles.
-
Chintagumpala M, Eckel SP, Krailo M, Morris M, Adesina A, Packer R, Lau C, Gajjar A. A pilot study using carboplatin, vincristine, and temozolomide in children with progressive/symptomatic low-grade glioma: a Children's Oncology Group study†. Neuro Oncol. 2015 Aug; 17(8):1132-8.
-
Horton TM, Ames MM, Reid JM, Krailo MD, Pendergrass T, Mosher R, Reaman GH, Seibel NL. A Phase 1 and pharmacokinetic clinical trial of paclitaxel for the treatment of refractory leukemia in children: a Children's Oncology Group study. Pediatr Blood Cancer. 2008 Apr; 50(4):788-92.
-
Franklin JL, Seibel NL, Krailo M, Fu C, Adamson PC, Reaman G. Phase 2 study of docetaxel in the treatment of childhood refractory acute leukemias: a Children's Oncology Group report. Pediatr Blood Cancer. 2008 Mar; 50(3):533-6.
-
Azuhata T, Scott D, Griffith TS, Miller M, Sandler AD. Survivin inhibits apoptosis induced by TRAIL, and the ratio between survivin and TRAIL receptors is predictive of recurrent disease in neuroblastoma. J Pediatr Surg. 2006 Aug; 41(8):1431-40.
-
Zwerdling T, Krailo M, Monteleone P, Byrd R, Sato J, Dunaway R, Seibel N, Chen Z, Strain J, Reaman G. Phase II investigation of docetaxel in pediatric patients with recurrent solid tumors: a report from the Children's Oncology Group. Cancer. 2006 Apr 15; 106(8):1821-8.
-
Furman WL, Crews KR, Billups C, Wu J, Gajjar AJ, Daw NC, Patrick CC, Rodriguez-Galindo C, Stewart CF, Dome JS, Panetta JC, Houghton PJ, Santana VM. Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors. J Clin Oncol. 2006 Feb 01; 24(4):563-70.
-
Janss AJ, Cnaan A, Zhao H, Shpilsky A, Levow C, Sutton L, Phillips PC. Synergistic cytotoxicity of topoisomerase I inhibitors with alkylating agents and etoposide in human brain tumor cell lines. Anticancer Drugs. 1998 Aug; 9(7):641-52.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|